For both fit and unfit patients, the current standard of care for relapsed or refractory (R/R) FLT3-mutated AML in the U.S. and Europe is single-agent gilteritinib; in Japan, single-agent quizartinib is also an option. Here, FLT3 is linked to acute myeloid leukemia.